AI Article Synopsis
- The serological responses to SARS-CoV-1 and SARS-CoV-2 show similarities that indicate prior exposure to other human coronaviruses may influence these responses.
- Some individuals with strong initial antibody responses to these viruses may experience worse clinical outcomes, suggesting that cross-reactive immunity can complicate disease severity.
- Research also highlights that pre-existing immunity from common cold coronaviruses may enhance the body's response to SARS-CoV-2, which poses challenges for developing effective vaccines and therapies.
Article Abstract
The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594548 | PMC |
| http://dx.doi.org/10.3389/fimmu.2020.567710 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!